SBC Medical Q4 EPS Surges 133% to $0.14, Profitability Improves Significantly
SBC sits 31% above its 52-week low of $2.91.
Summary
SBC Medical Group announced strong fourth-quarter 2025 financial results, with earnings per share (EPS) surging 133% year-over-year to $0.14 and net income increasing 117% to $14 million. For the full year 2025, EPS grew 4% to $0.50 and net income rose 9% to $51 million. Despite an 11% decline in Q4 revenue and a 15% decline for the full year, the company's profitability significantly improved, which management attributed to successful business restructuring and revised franchise fee arrangements. This report indicates that the company's strategic shifts are positively impacting its bottom line. Traders will be watching for continued profitability expansion and signs of revenue stabilization in upcoming quarters.
At the time of this announcement, SBC was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $389.8M. The 52-week trading range was $2.91 to $5.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.